Use of theranostics has increased, with targeted treatment now including radium-223 for treatment of skeletal metastatic disease [37], the use of [177Lu]-dotatate therapy for neuroendocrine tumours [38], and [177Lu]-PSMA-617 therapy for prostate cancer [5]. This evidence concerns the gene FOLH1 and prostate carcinoma.